Defect of Heparin Binding in Plasma and Recombinant von Willebrand Factor with Type 2 von Willebrand Disease Mutations

Ghassem Rastegar-Lari; Nadine Ajzenberg; Anne-Sophie Ribba; Valérie Vereycken-Holler; Paulette Legendre; Bruno O. Villoutreix; Dominique Meyer; Dominique Baruch

doi:10.1055/s-0037-1616749

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2001; 86(06): 1459-1465
DOI: 10.1055/s-0037-1616749

Review Article

Schattauer GmbH

Defect of Heparin Binding in Plasma and Recombinant von Willebrand Factor with Type 2 von Willebrand Disease Mutations

Ghassem Rastegar-Lari

¹INSERM U143, Bicetre and INSERM U428, Paris, France

,

Nadine Ajzenberg

¹INSERM U143, Bicetre and INSERM U428, Paris, France

,

Anne-Sophie Ribba

¹INSERM U143, Bicetre and INSERM U428, Paris, France

,

Valérie Vereycken-Holler

¹INSERM U143, Bicetre and INSERM U428, Paris, France

,

Paulette Legendre

¹INSERM U143, Bicetre and INSERM U428, Paris, France

,

Bruno O. Villoutreix

¹INSERM U143, Bicetre and INSERM U428, Paris, France

,

Dominique Meyer

¹INSERM U143, Bicetre and INSERM U428, Paris, France

,

Dominique Baruch

¹INSERM U143, Bicetre and INSERM U428, Paris, France

› Institutsangaben

Abstract

Summary

The aim of our study was to characterise heparin-binding properties of mutated von Willebrand factor (VWF) in 24 patients plasmas with type 2 von Willebrand disease (VWD), and in 15 recombinant VWF (rVWF) with the corresponding mutations. Binding of mutated rVWF or plasma VWF was compared to that of WT-rVWF or normal pool plasma VWF. Four mutations, at positions C509, V551, R552 and R611 lead to significantly decreased binding to heparin in both plasma and rVWF. Interestingly, whereas these four residues are distant in the primary structure of VWF-A1 domain, they are close to each other in its three-dimensional structure. Structural analysis suggested how folding problems and destabilisation due to these mutations could induce reorganisation of surface regions involved in heparin binding. In contrast, no heparin-binding defect was found associated with different type 2 VWF mutants, at positions G561, E596, I662, R543, R545, V553, R578 or L697.

Keywords

Heparin - von Willebrand factor - von Willebrand disease

Volltext

Referenzen

References
1 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
2 Ginsburg D, Sadler JE. von Willebrand disease: a database of point mutations, insertions, and deletions. Thromb Haemost 1993; 69: 177-84.
3 Meyer D, Fressinaud E, Hilbert L, Ribba AS, Lavergne JM, Mazurier C. Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function In: Best Practice & Research Clinical Haematology. R. Michiels, ed. London: Harcourt Publishers; 2001. Vol 14, No. 2 (In press).
4 Ribba AS, Hilbert L, Lavergne JM, Fressinaud E, Boyer-Neumann C, Ternisien C, Juhan-Vague I, Goudemand J, Girma JP, Mazurier C, Meyer D. The Arg552Cys mutation within the A1 loop of von Willebrand Factor (VWF) induces an abnormal folding with a loss-of-function resulting in a 2A-like phenotype. Study of ten patients and of mutated recombinant VWF. Blood 2000; 97: 952-9.
5 Veyradier A, Fressinaud E, Meyer D. Laboratory diagnosis of von Willebrand disease. Inter J Clin Lab Res 1998; 28: 201-10.
6 Rastegar-Lari G, Legendre P, Ajzenberg N, Warszawski J, Meyer D, Baruch D. von Willebrand factor binding to heparin in various types of von Willebrand disease. Hematology J 2000; 1: 190-8.
7 Fujimura Y, Titani K, Holland LZ, Roberts JR, Kostel P, Ruggeri ZM, Zimmerman TS. A heparin-binding domain of human von Willebrand factor. J Biol Chem 1987; 262: 1734-9.
8 Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. J Biol Chem 1989; 264: 17361-7.
9 Sobel M, Soler D, Kermode J, Harris R. Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. J Biol Chem 1992; 267: 8857-62.
10 Fretto LJ, Fowler WE, McCaslin DR, Erickson HP, McKee PA. Substructure of human von Willebrand factor: proteolysis by V-8 and characterization of two functional domains. J Biol Chem 1986; 261: 15679-89.
11 Sixma JJ, Schiphorst ME, Verweij CL, Pannekoek H. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur J Biochem 1991; 196: 369-75.
12 Kroner PA, Frey AB. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine-scanning mutagenesis. Biochemistry 1996; 35: 13460-8.
13 Lavergne JM, de Paillette L, Bahnak BR, Ribba AS, Fressinaud E, Meyer D, Pietu G. Defects in type IIA von Willebrand disease: a cysteine 509 to arginine substitution in the mature von Willebrand factor disrupts a disulphide loop involved in the interaction with platelet glycoprotein Ib-IX. Br J Haemat 1992; 82: 66-72.
14 Ribba AS, Christophe O, Derlon A, Cherel G, Siguret V, Lavergne JM, Girma JP, Meyer D, Pietu G. Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease. Blood 1994; 83: 833-41.
15 Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE. Molecular basis of von Willebrand disease type-IIB – candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein-Ib binding sequences. J Clin Invest 1991; 87: 1220-6.
16 Cooney KA, Nichols WC, Bruck ME, Bahou WF, Shapiro AD, Bowie EJW, Gralnick HR, Ginsburg D. The molecular defect in type-IIB von Willebrand disease – Identification of four potential missense mutations within the putative GPIb binding domain. J Clin Invest 1991; 87: 1227-33.
17 Randi AM, Jorieux S, Tuley EA, Mazurier C, Sadler JE. Recombinant von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin. J Biol Chem 1992; 267: 21187-92.
18 Hillery CA, Mancuso DJ, Sadler JE, Ponder JW, Jozwiak MA, Christopherson PA, Gill C, Scott P, Montgomery RR. Type 2M von Wille-brand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998; 91: 1572-81.
19 Hilbert L, Gaucher C, Mazurier C. Identification of two mutations (Arg 611 Cys and Arg 611 His) in the A1 loop responsible for type 2 von Willebrand disease with decreased platelet dependent function of von Willebrand factor. Blood 1995; 86: 1010-8.
20 Voorberg J, Fontijn R, van Mourik JA, Pannekoek H. Domains involved in multimer assembly of von Willebrand factor (VWF). Multimerization is independent of dimerization. EMBO J 1990; 9: 797-803.
21 Matsushita T, Sadler JE. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1995; 270: 13406-14.
22 Siguret V, Ribba AS, Christophe O, Cherel G, Obert B, Rouault C, Nishikubo T, Meyer D, Girma JP, Pietu G. Characterization of recombinant von Willebrand factors mutated on cysteine 509 or 695. Thromb Haemost 1996; 76: 453-9.
23 Ajzenberg N, Ribba AS, Rastegar-Lari G, Meyer D, Baruch D. Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation. Blood 2000; 95: 3796-802.
24 Hilbert L, Gaucher C, Fressinaud E, Meyer D, Mazurier C. A new type 2M (“type B”) VWD mutation (G1324A) also at position 561 of the mature VWF subunit. Thromb Haemost. 1997 77 suppl: 654 (abstr).
25 Hilbert L, Gaucher C, Mazurier C. Effects of different amino-acid substitutions in the leucine 649-proline 708 segment of recombinant von Willebrand factor. Br J Haemat 1995; 91: 983-90.
26 Hilbert L, Gaucher C, de Romeuf C, Horellou MH, Vink T, Mazurier C. Leu 697Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood 1994; 83: 1542-50.
27 Lankhof H, Wu YP, Vink T, Schiphorst ME, Zerwes HG, de Groot PG, Sixma JJ. Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor. Blood 1995; 86: 1035-42.
28 Pietu G, Ribba AS, Cherel G, Siguret V, Obert B, Rouault C, Ginsburg D, Meyer D. Epitope mapping of inhibitory monoclonal antibodies to human von Willebrand factor by using recombinant cDNA libraries. Thromb Haemost 1994; 71: 788-92.
29 Christophe O, Rouault C, Obert B, Pietu G, Meyer D, Girma JP. A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the A1 disulphide loop (Cys509-Cys695) discriminates beween type 2A and type 2B von Willebrand disease. Br J Haemat 1995; 90: 195-203.
30 Schullek J, Jordan J, Montgomery RR. Interaction of von Willebrand factor with human platelets in the plasma milieu. J Clin Invest 1984; 73: 421-8.
31 Baruch D, Ajzenberg N, Denis C, Legendre P, Lormeau JC, Meyer D. Binding of heparin fractions to von Willebrand factor: effect of molecular weight and affinity for antithrombin III. Thromb Haemost 1994; 71: 141-6.
32 de Romeuf C, Mazurier C. Heparin binding assay of von Willebrand factor (VWF) in plasma milieu – evidence of the importance of the multimerization degree of VWF. Thromb Haemost 1993; 69: 436-40.
33 Matsushita T, Meyer D, Sadler JE. Localization of von Willebrand Factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-Alanine scanning mutagenesis. J Biol Chem 2000; 275: 11044-9.
34 Nitu-Walley IC, Riddell A, Lee CA, Pasi KJ, Owens D, Enayat MS, Perkins SJ, Jenkins PV. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes geno-types and molecular modelling. Thromb Haemost 2000; 84: 998-1004.
35 Celikel R, Varughese KI, Madhusudan Yoshioka A, Ware J, Ruggeri ZM. Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Nature Struct Biol 1998; 5: 189-94.
36 Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem 1998; 273: 10396-401.